Maxcyte (MXCT) Current Deferred Revenue (2020 - 2026)

Maxcyte (MXCT) has 7 years of Current Deferred Revenue data on file, last reported at $3.3 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $3.3 million, down 21.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (down 21.09% YoY), and the FY2025 annual result was $3.6 million, down 31.48% from the prior year.
• Current Deferred Revenue fell to $3.3 million in Q1 2026 per MXCT's latest filing, from $3.6 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $7.3 million in Q2 2022 and troughed at $2.6 million in Q2 2025.
• A 5-year average of $5.1 million and a median of $5.2 million in 2025 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue sank 35.81% in 2023, then grew 19.1% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $6.7 million in 2022, then retreated by 24.49% to $5.1 million in 2023, then gained by 3.59% to $5.3 million in 2024, then plunged by 31.48% to $3.6 million in 2025, then decreased by 9.09% to $3.3 million in 2026.
• Business Quant data shows MXCT's Current Deferred Revenue at $3.3 million in Q1 2026, $3.6 million in Q4 2025, and $5.2 million in Q3 2025.